DARE Latest News, Press Relases and Analysis

All

Press Releases

10 hours ago - By: Daré Bioscience, Inc.

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

18 days ago - By: The Motley Fool

Daré Bioscience (DARE) Q3 2025 Earnings Transcript

18 days ago - By: Zacks Investment Research - Mentions: PHR

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

18 days ago - By: Daré Bioscience, Inc.

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

19 days ago - By: Zacks Investment Research - Mentions: CRBU

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

19 days ago - By: Benzinga

What to Expect from Dare Bioscience's Earnings

4 months ago - By: The Motley Fool

Daré Bioscience Posts Narrower Q2 Loss

4 months ago - By: Benzinga

A Preview Of Dare Bioscience's Earnings

20 days ago - By: Daré Bioscience, Inc.

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

21 days ago - By: Zacks Investment Research - Mentions: EDIT

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

25 days ago - By: Zacks Investment Research - Mentions: STRO

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

25 days ago - By: Daré Bioscience, Inc.

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

a month ago - By: Zacks Investment Research - Mentions: ACLX

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: ACIU

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

2 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic

2 months ago - By: Daré Bioscience, Inc.

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

4 months ago - By: Zacks Investment Research - Mentions: AUNA

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: IMTX

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: EDIT

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: CCCC

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

4 months ago - By: Zacks Investment Research - Mentions: ARVN

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Daré Bioscience, Inc.

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

4 months ago - By: Daré Bioscience, Inc.

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

4 months ago - By: Daré Bioscience, Inc.

DARE BIOSCIENCE INC (DARE) Stock News

DARE Latest News, Press Relases and Analysis